Late Breaking Abstract - SHAMAL: reduction of maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab: a randomised phase 4 study

被引：1

作者：

Jackson, David J. ^{[1
]}

Heaney, Liam G. ^{[2
]}

Humbert, Marc ^{[3
]}

Kent, Brian D. ^{[4
]}

Hiljemark, Lina ^{[5
]}

Olinger, Lynda ^{[6
,7
]}

Cohen, David ^{[8
]}

Menzies-Gow, Andrew ^{[9
]}

Korn, Stephanie ^{[10
,11
]}

机构：

[1] Kings Coll London, Sch Immunol & Microbial Sci, London, England

[2] Queens Univ Belfast, Wellcome Wolfoson Inst Expt Med, Belfast, Antrim, North Ireland

[3] Univ Paris Saclay, Serv Pneumol, Hop Bicetre, Le Kremlin Bicetre, France

[4] St James Hosp, Dublin, Ireland

[5] AstraZeneca, Evidence Delivery, Gothenburg, Sweden

[6] AstraZeneca, LateStage Dev Resp & Immunol, Cambridge, England

[7] Cytel Inc, Waltham, MA USA

[8] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Gaithersburg, MD USA

[9] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Cambridge, England

[10] Thoraxklin Heidelberg & IKF Pneumol, Heidelberg, Germany

[11] Thoraxklin Heidelberg & IKF Pneumol, Mainz, Germany

来源：

关键词：

Asthma; -; management; Severe asthma;

D O I：

10.1183/13993003.congress-2023.RCT798

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：3